

INTRODUCTION	XXVII
STUDY GOALS AND OBJECTIVES.....	XXVII
REASONS FOR DOING THE STUDY	XXVII
INTENDED AUDIENCE.....	XXVIII
SCOPE OF REPORT	XXVIII
INFORMATION SOURCES.....	XXVIII
ANALYST’S CREDENTIALS.....	XXIX
RELATED REPORTS FROM BCC RESEARCH	XXIX
BCC ONLINE SERVICES.....	XXIX
DISCLAIMER	XXIX
 SUMMARY.....	 XXX
THE CARDIOVASCULAR DIAGNOSTIC, DRUG, AND DEVICE MARKETS	 XXX
<i>SUMMARY TABLE WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, THROUGH 2012 (\$ BILLIONS)</i>	 XXXII
<i>SUMMARY FIGURE WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, 2005-2012 (\$ BILLIONS)</i>	 XXXII
 OVERVIEW	 1
WHAT IS CARDIOVASCULAR (CV) DISEASE?	1
CAUSES OF CARDIOVASCULAR DISEASE	1
CAUSES OF CARDIOVASCULAR DISEASE (CONTINUED)	2
CARDIOVASCULAR DIAGNOSTICS.....	3
CARDIOVASCULAR MEDICINE	3
CARDIOVASCULAR DEVICES	3
 CARDIOVASCULAR DISEASES	 4
DISEASES OF THE HEART (CARDIO) AND DISEASES OF THE BLOOD VESSELS (VASCULAR).....	 4
DISEASES OF THE HEART.....	4
Coronary Artery Disease (CAD).....	4
Coronary Heart Disease (CHD)	5
Cardiomyopathy	5
Valvular Heart Disease.....	5
Pericardial Disease.....	5
Congenital Heart Disease	6
Heart Failure	6
DISEASE OF BLOOD VESSELS	6
Arteriosclerosis and Atherosclerosis.....	6
High Blood Pressure.....	6
Stroke	7
Aneurysm	7

Peripheral Arterial Disease and Claudication (PAD)	7
Vasculitis.....	7
Venous Incompetence	8
Venous Thrombosis	8
Varicose Veins.....	8
Lymphedema	8
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE	8
Global Distribution Pattern in 2004	9
Age.....	9
Gender.....	10
Role of Risk Factors	10
Risk Factors	10
Psychological and Social Factors	11
Prevention of Cardiovascular Disease	11
PREVALANCE OF CARDIOVASCULAR DISEASES	12
MAJOR CAUSE OF DEATH.....	12
THE EPIDEMIOLOGICAL TRANSITION.....	12
PREVALENCE OF HEART DISEASE IN VARIOUS	
CATEGORIES.....	13
Age.....	13
Gender.....	13
Race/ Ethnicity.....	13
Education	13
<i>TABLE 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION,</i>	
<i>AND ANGINA PECTORIS BY VARIOUS CATEGORIES, 2005.....</i>	<i>14</i>
<i>FIGURE 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION,</i>	
<i>AND ANGINA PECTORIS BY AGE GROUP, 2005 (%).....</i>	<i>15</i>
<i>FIGURE 2 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION,</i>	
<i>AND ANGINA PECTORIS BY GENDER, 2005 (%).....</i>	<i>15</i>
<i>FIGURE 3 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION,</i>	
<i>AND ANGINA PECTORIS BY RACE/ETHNICITY, 2005 (%).....</i>	<i>16</i>
<i>FIGURE 4 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION,</i>	
<i>AND ANGINA PECTORIS BY EDUCATION 2005 (%).....</i>	<i>16</i>
PREVALENCE OF CARDIOVASCULAR DISEASES IN THE	
U.S.	17
<i>TABLE 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN U.S.,</i>	
<i>2005 (MILLION PEOPLE).....</i>	<i>17</i>
<i>FIGURE 5 PREVALENCE OF CARDIOVASCULAR DISEASES IN THE</i>	
<i>U.S., 2005 (MILLION PEOPLE).....</i>	<i>18</i>
COST OF CARDIOVASCULAR DISEASES IN THE U.S.	18
<i>TABLE 3 COST OF CARDIOVASCULAR DISEASES IN U.S. THROUGH</i>	
<i>2012 (\$ BILLIONS).....</i>	<i>19</i>
<i>FIGURE 6 COST OF CARDIOVASCULAR DISEASES IN THE U.S.,</i>	
<i>2005–2012 (\$ BILLIONS).....</i>	<i>19</i>

PREVALENCE AND COST OF CARDIOVASCULAR DISEASES IN EUROPE	19
MORTALITY DUE TO CARDIOVASCULAR DISEASES	20
U.S.	20
<i>TABLE 4 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)</i>	20
<i>TABLE 4 (CONTINUED)</i>	21
<i>FIGURE 7 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S. 2005 (%)</i>	21
Europe	21
<i>TABLE 5 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN EUROPE, 2005 (%)</i>	22
<i>FIGURE 8 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)</i>	22
REGULATORY ISSUES	23
CARDIOVASCULAR DRUGS APPROVED BY FDA	23
<i>TABLE 6 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002–2007*</i>	23
<i>FIGURE 9 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002–2007*</i>	24
CARDIOVASCULAR DEVICES APPROVED BY THE FDA	24
<i>TABLE 7 CARDIOVASCULAR DEVICES APPROVED BY THE FDA, 2002–2007*</i>	25
<i>TABLE 7 (CONTINUED)</i>	26
<i>TABLE 7 (CONTINUED)</i>	27
<i>FIGURE 10 CARDIOVASCULAR DEVICES APPROVED BY THE FDA 2002–2007*</i>	28
CARDIOVASCULAR DRUGS RECALLED BY FDA.....	28
<i>TABLE 8 CARDIOVASCULAR DRUGS RECALLED BY THE FDA, 2002–2007*</i>	29
CARDIOVASCULAR DEVICES RECALLED BY FDA	29
<i>TABLE 9 CARDIOVASCULAR DEVICES RECALLED BY THE FDA, 2002–2007*</i>	30
<i>TABLE 9 (CONTINUED)</i>	31
<i>FIGURE 11 CARDIOVASCULAR DEVICES RECALLED BY FDA, 2002–2007*</i>	31
<i>FIGURE 11 (CONTINUED)</i>	32
NEW DRUG APPLICATIONS	32
NEW DRUG APPLICATIONS (CONTINUED)	32
NEW DRUG APPLICATIONS (CONTINUED).....	33
CARDIOVASCULAR DIAGNOSTICS.....	34
DIAGNOSTICS DEFINITION	34
<i>IN VITRO</i> DIAGNOSTIC	34

BIOMARKERS	34
Aspartate Aminotransferase (AST/GOT)	35
Lactate Dehydrogenase and its Isoenzyme LD	35
Creatine Kinase (CK) and its Isoenzyme MB.....	35
Myoglobin.....	36
Cardiac Troponins	36
Reasons behind the Replacement of CKMB with	
Troponins	37
Myoglobin/Carbonic Anhydrase III Ratio.....	37
Glycogen Phosphorylase Isoenzyme BB	38
Heart Type Fatty Acid Binding Protein	38
COMPARISON BETWEEN CTNT AND CTNL	39
Natriuretic Peptides as Cardiac Biomarkers	39
<i>TABLE 10 NT-PROBNP IN ACUTE SITUATIONS</i>	40
<i>TABLE 11 NT-PROBNP IN PRIMARY CARE SETTING</i>	41
POINT-OF-CARE TESTING	41
NEED FOR THE POCT	42
<i>TABLE 12 ADVANTAGES OF POINT OF CARE TESTING</i>	42
<i>TABLE 13 DISADVANTAGES OF POINT OF CARE TESTING</i>	43
Past, Present, and Future of Point-of-Care Testing.....	43
Past.....	43
Present	43
Future.....	44
DETERMINING WHETHER TO USE POC CARDIAC	
TESTING IN THE ED	44
Considerations of Turnaround Times	44
The Importance of Quantitative Results	45
Concerns about Standardization.....	45
VENUES FOR POC TESTING.....	45
<i>TABLE 14 VENUES FOR POC TESTING</i>	46
IN VIVO DIAGNOSTICS.....	46
ECHOCARDIOGRAPHY	46
Need of the Echocardiography	47
<i>TABLE 15 TYPES OF ECHOCARDIOGRAMS</i>	47
ULTRASOUND	47
<i>TABLE 16 TYPES OF DOPPLER ULTRASOUND</i>	48
Advantages of Ultrasound.....	48
MRI	49
Need of MRI Scan	49
POSITRON EMISSION TOMOGRAPHY	50
COMPUTED TOMOGRAPHY.....	50
Electron-Beam Computed Tomography (EBCT or	
Ultrafast CT)	50
Electron-Beam Computed (Continued).....	51

CARDIOVASCULAR THERAPY	52
CARDIOVASCULAR DRUGS	52
ANTI-ANGINAL AGENTS	52
<i>TABLE 17 COMMONLY USED ANTI-ANGINAL AGENTS</i>	53
ANTI-ARRHYTHMIC AGENTS	53
<i>TABLE 18 COMMONLY USED ANTI-ARRHYTHMIC AGENTS</i>	54
ANTI-HYPERTENSIVE DRUGS	54
<i>TABLE 19 COMMONLY USED ANTI-HYPERTENSIVE AGENTS</i>	55
ANTI-THROMBOTIC AGENTS	55
BLOOD LIPID LOWERING AGENTS	56
<i>TABLE 20 COMMONLY USED BLOOD LIPID LOWERING AGENTS</i>	57
DRUGS USED TO TREAT CONGESTIVE HEART FAILURE	57
<i>TABLE 21 COMMONLY USED DRUGS TO TREAT CONGESTIVE</i> <i>HEART FAILURE</i>	58
CARDIOVASCULAR DEVICES	58
PACEMAKERS	59
<i>TABLE 22 PACEMAKERS</i>	59
Defibrillators.....	59
Manual External Defibrillators	60
Manual Internal Defibrillator	60
Automated External Defibrillator	60
Semi-automated External Defibrillator	60
Implantable Cardioverter Defibrillator	60
Drug-Eluting Stents (DES)	61
Catheters.....	61
Valves.....	62
Mechanical Heart Valve	62
Biological Heart Valve	62
Ventricular Assist Device	63
Guidewires	63
Artificial Heart	63
CARDIAC RESYNCHRONIZATION THERAPY	64
Cardiac Resynchronization Therapy	64
Cardiac Resynchronization Therapy Devices.....	64
Difference between Biventricular Pacemaker and Standard Pacemaker.....	65
Use of CRT	65
Benefits of CRT.....	65
Potential Risks with Biventricular Pacemakers	66
INDUSTRY STRUCTURE	67
CARDIOVASCULAR DIAGNOSTICS	67
CARDIAC BIOMARKERS	67
<i>TABLE 23 PRESENT CARDIAC MARKER TESTING</i>	67
Market Shares for Companies Providing Biomarker Tests.....	67

<i>TABLE 24 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)</i>	67
<i>FIGURE 12 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)</i>	68
Effect of POCT on the Growth of Cardiac Biomarker Testing in Laboratory	68
POINT OF TESTING FOR CARDIAC BIOMARKERS	69
<i>TABLE 25 PRESENT POINT-OF-CARE TESTING FOR CARDIAC BIOMARKERS</i>	69
Market Shares for Companies Providing Biomarker Tests.....	69
<i>TABLE 26 MARKET SHARE OF COMPANIES PROVIDING POINT-OF-CARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)</i>	69
<i>FIGURE 13 MARKET SHARE OF COMPANIES PROVIDING POINT-OF-CARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)</i>	70
Factors Influencing the Growth of Point-of-Care Testing	70
Challenges for the Manufacturers	71
IN-VIVO DIAGNOSTICS.....	71
<i>TABLE 27 PRESENT IMAGING SYSTEMS FOR IN-VIVO DIAGNOSIS</i>	71
Market Shares for Companies Providing <i>In-Vivo</i> Diagnostics	72
<i>TABLE 28 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)</i>	72
<i>FIGURE 14 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)</i>	72
Factors Affecting the Growth of Cardiac Imaging or <i>In vivo</i> Diagnostics.....	73
CARDIOVASCULAR DRUGS	73
ANTI-ANGINAL AGENTS	74
<i>TABLE 29 GLOBAL MARKET LEADERS OF ANTI-ANGINAL AGENTS</i>	74
Market Shares for Anti-anginal Agents	74
<i>TABLE 30 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ANGINAL AGENTS, 2006 (%)</i>	74
<i>FIGURE 15 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ANGINAL AGENTS, 2006 (%)</i>	75
ANTI-ARRHYTHMIC AGENTS.....	75
<i>TABLE 31 GLOBAL MARKET LEADERS OF ANTI-ARRHYTHMIC AGENTS</i>	75
Market Shares for Anti-arrhythmic Agents	76
<i>TABLE 32 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ARRHYTHMIC AGENTS, 2006 (%)</i>	76
<i>FIGURE 16 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ARRHYTHMIC AGENTS, 2006 (%)</i>	76
ANTI-HYPERTENSIVE AGENTS.....	77

<i>TABLE 33 GLOBAL MARKET LEADERS OF ANTI-HYPERTENSIVE AGENTS</i>	77
Market Shares for Anti-hypertensive Agents	77
<i>TABLE 34 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-HYPERTENSIVE AGENTS, 2006 (%)</i>	78
<i>FIGURE 17 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-HYPERTENSIVE AGENTS, 2006 (%)</i>	78
ANTI-THROMBOTIC AGENTS.....	79
<i>TABLE 35 GLOBAL MARKET LEADERS OF ANTI-THROMBOTIC AGENTS</i>	79
Market Shares for Anti-thrombotic Agents.....	79
<i>TABLE 36 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-THROMBOTIC AGENTS, 2006 (%)</i>	79
<i>FIGURE 18 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-THROMBOTIC AGENTS, 2006 (%)</i>	80
BLOOD LIPID LOWERING AGENTS	80
<i>TABLE 37 GLOBAL MARKET LEADERS OF BLOOD LIPID LOWERING AGENTS</i>	80
Market Shares for Blood Lipid Lowering Agents.....	81
<i>TABLE 38 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)</i>	81
<i>FIGURE 19 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)</i>	81
DRUGS TREATING CONGESTIVE HEART FAILURE.....	82
<i>TABLE 39 GLOBAL MARKET LEADERS OF DRUGS TREATING CONGESTIVE HEART FAILURE</i>	82
Market Shares for Drugs Treating Congestive Heart Failure	82
<i>TABLE 40 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)</i>	82
<i>TABLE 40 (CONTINUED)</i>	83
<i>FIGURE 20 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)</i>	83
FACTORS AFFECTING THE SALES OF CARDIOVASCULAR DRUGS	83
Price Control/Price pressure	84
Expiration of Patents	84
MAJOR FACTORS FOR FUTURE GROWTH	84
Life Expectancy	84
Access of Senior Citizens to Prescription Drugs	85
Patent Protection.....	85
Drugs Portfolio Management.....	85
Significant Potential of Developing Countries	85
CARDIOVASCULAR DEVICES	85

PACEMAKERS	86
<i>TABLE 41 GLOBAL MARKET LEADERS OF MANUFACTURERS OF PACEMAKERS</i>	86
Market Shares of Companies Manufacturing Pacemakers	86
<i>TABLE 42 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)</i>	87
<i>FIGURE 21 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)</i>	87
CARDIOVERTER DEFIBRILLATORS.....	87
<i>TABLE 43 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CONVENTIONAL CARDIOVERTER DEFIBRILLATORS</i>	88
<i>TABLE 44 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CRT-DEFIBRILLATORS</i>	88
Market Shares of Companies Manufacturing Conventional Cardioverter Defibrillators	89
<i>TABLE 45 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)</i>	89
<i>FIGURE 22 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)</i>	89
Market Shares of Companies Manufacturing CRT- Defibrillators	90
<i>TABLE 46 MARKET SHARE OF COMPANIES MANUFACTURING CRT-DEFIBRILLATORS, 2006 (%)</i>	90
<i>FIGURE 23 MARKET SHARE OF COMPANIES MANUFACTURING CRT-DEFIBRILLATORS, 2006 (%)</i>	90
DRUG ELUTING STENTS	91
<i>TABLE 47 GLOBAL MARKET LEADERS OF MANUFACTURERS OF DRUG ELUTING STENTS</i>	91
Market Shares of Companies Manufacturing Drug Eluting Stents	91
<i>TABLE 48 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)</i>	91
<i>FIGURE 24 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)</i>	92
CATHETERS.....	92
<i>TABLE 49 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CATHETERS</i>	92
<i>TABLE 49 (CONTINUED)</i>	93
Market Shares of Companies Manufacturing Catheters.....	93
<i>TABLE 50 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)</i>	93
<i>FIGURE 25 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)</i>	94
HEART VALVES.....	94

<i>TABLE 51 GLOBAL MARKET LEADERS OF MANUFACTURERS OF HEART VALVES</i>	94
Market Shares of Companies Manufacturing Heart Valves.....	95
<i>TABLE 52 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)</i>	95
<i>FIGURE 26 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)</i>	96
VENTRICULAR ASSIST DEVICE	96
<i>TABLE 53 GLOBAL MARKET LEADERS OF MANUFACTURERS OF VENTRICULAR ASSIST DEVICES</i>	96
Market Shares of Companies Manufacturing Ventricular Assist Devices.....	96
<i>TABLE 54 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)</i>	97
<i>FIGURE 27 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)</i>	97
GUIDE WIRES.....	98
<i>TABLE 55 GLOBAL MARKET LEADERS OF MANUFACTURERS OF GUIDE WIRES</i>	98
Market Shares of Companies Manufacturing Guidewires	98
<i>TABLE 56 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)</i>	98
<i>FIGURE 28 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)</i>	99
FACTORS AFFECTING THE SALES OF CARDIOVASCULAR DEVICES	99
Aging Baby-Boomers	99
Regulation.....	99
Competitive Landscape of Technology.....	100
Shortening of Patent Lives.....	100
Business Taxes	100
MARKET ANALYSIS OF CARDIOVASCULAR DIAGNOSTICS	101
CARDIAC BIOMARKERS	101
<i>TABLE 57 GLOBAL SALES OF CARDIAC BIOMARKERS, THROUGH 2012 (\$ MILLIONS)</i>	102
<i>FIGURE 29 GLOBAL SALES OF CARDIAC BIOMARKERS, 2005-2012 (\$ MILLIONS)</i>	103
CARDIAC MARKER TESTING BY TYPE	103
<i>TABLE 58 ESTIMATED WORLDWIDE MARKET FOR CARDIAC MARKER TESTING BY TYPE, THROUGH 2012 (\$ MILLIONS)</i>	104
<i>FIGURE 30 GLOBAL SALES OF CARDIAC BIOMARKERS, BY TYPE, 2005-2012 (\$ MILLIONS)</i>	105
POINT-OF-CARE TESTING	105

TABLE 59 GLOBAL SALES OF POINT-OF-CARE TESTING, THROUGH 2012 (\$ MILLIONS).....	106
FIGURE 31 GLOBAL SALES OF POINT-OF-CARE TESTING, 2005- 2012 (\$ MILLIONS).....	107
IN VIVO DIAGNOSTICS.....	107
<i>In Vivo</i> Diagnostics (Continued)	108
TABLE 60 GLOBAL SALES OF IN-VIVO DIAGNOSTICS, THROUGH 2012 (\$ MILLIONS).....	109
FIGURE 32 GLOBAL SALES OF IN VIVO DIAGNOSTICS. 2005-2012 (\$ MILLIONS).....	109
TOTAL MARKET SHARES OF CARDIOVASCULAR DIAGNOSTICS WORLDWIDE.....	110
TABLE 61 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%).....	110
FIGURE 33 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%).....	110
MARKET ANALYSIS OF CARDIOVASCULAR DRUGS	111
ANTI-ANGINAL AGENTS.....	111
TABLE 62 GLOBAL SALES OF ANTI-ANGINAL DRUGS, THROUGH 2012 (\$ BILLIONS).....	112
FIGURE 34 GLOBAL SALES OF ANTI-ANGINAL DRUGS, 2005-2012 (\$ BILLIONS).....	112
ANTI-ARRHYTHMIC AGENTS.....	113
TABLE 63 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, THROUGH 2012 (\$ BILLIONS)	113
FIGURE 35 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, 2005- 2012 (\$ BILLIONS).....	114
ANTI-HYPERTENSIVE AGENTS.....	114
TABLE 64 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, THROUGH 2012 (\$ BILLIONS)	115
FIGURE 36 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, 2005- 2012 (\$ BILLIONS).....	116
ANTI-THROMBOTIC AGENTS.....	117
TABLE 65 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, THROUGH 2012 (\$ BILLIONS)	118
FIGURE 37 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, 2005- 2012 (\$ BILLIONS).....	118
BLOOD LIPID LOWERING AGENTS	119
TABLE 66 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, THROUGH 2012 (\$ BILLIONS)	120
FIGURE 38 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, 2005-2012 (\$ BILLIONS).....	120
DRUGS USED TO TREAT CONGESTIVE HEART FAILURE	121

TABLE 67 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, THROUGH 2012 (\$ BILLIONS)	122
FIGURE 39 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, 2005-2012 (\$ BILLIONS).....	122
TOTAL WORLDWIDE MARKET SHARES OF CARDIOVASCULAR DRUGS.....	123
TABLE 68 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006 (%).....	123
FIGURE 40 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006 (%).....	124
CARDIOVASCULAR DEVICES MARKET ANALYSIS	125
PACEMAKERS.....	125
TABLE 69 GLOBAL SALES OF PACEMAKERS, THROUGH 2012 (\$ MILLIONS).....	126
FIGURE 41 GLOBAL SALES OF PACEMAKERS, 2005-2012 (\$ MILLIONS).....	126
IMPLANTABLE CARDIOVERTER DEFIBRILLATORS.....	127
TABLE 70 GLOBAL SALES OF CONVENTIONAL IMPLANTABLE CARDIOVERTER DEVICES, THROUGH 2012 (\$ MILLIONS).....	128
FIGURE 42 GLOBAL SALES OF IMPLANTABLE CARDIOVERTER DEVICES, 2005-2012 (\$ MILLIONS).....	129
TABLE 71 GLOBAL SALES OF CRT-DEFIBRILLATORS, THROUGH 2012 (\$ MILLIONS).....	130
FIGURE 43 GLOBAL SALES OF IMPLANTABLE CRT- DEFIBRILLATORS, 2005-2012 (\$ MILLIONS).....	130
DRUG ELUTING STENTS (DES) AND GRAFTS	131
Drug Eluting Stents (DES) and Grafts (Continued)	132
TABLE 72 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, THROUGH 2012 (\$ MILLIONS)	133
FIGURE 44 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, 2005-2012 (\$ MILLIONS).....	133
CATHETERS.....	134
TABLE 73 GLOBAL SALES OF CATHETERS, THROUGH 2012 (\$ MILLIONS).....	135
FIGURE 45 GLOBAL SALES OF CATHETERS, 2005-2012 (\$ MILLIONS).....	135
HEART VALVES.....	136
TABLE 74 GLOBAL SALES OF HEART VALVES, THROUGH 2012 (\$ MILLIONS).....	137
FIGURE 46 GLOBAL SALES OF HEART VALVES, THROUGH 2012 (\$ MILLIONS).....	137
VENTRICULAR ASSIST DEVICES	138
TABLE 75 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, THROUGH 2012 (\$ MILLIONS).....	139

<i>FIGURE 47 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, 2005-2012 (\$ MILLIONS)</i>	139
GUIDEWIRES.....	140
<i>TABLE 76 GLOBAL SALES OF GUIDEWIRES, THROUGH 2012 (\$ MILLIONS)</i>	141
<i>FIGURE 48 GLOBAL SALES OF GUIDEWIRES, 2005-2012 (\$ MILLIONS)</i>	141
ARTIFICIAL HEART.....	142
TOTAL MARKET SHARES OF CARDIOVASCULAR DEVICES WORLDWIDE.....	142
<i>TABLE 77 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)</i>	142
<i>FIGURE 49 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)</i>	143
NEW DEVELOPMENTS/TECHNOLOGICAL INNOVATIONS	144
DIAGNOSTICS.....	144
SIEMENS MEDICAL SOLUTIONS	144
NEUROSONIX LTD	144
UNIVERSITY HOSPITAL MANNHEIM AND OSPEDALI RIUNITI DI BERGAMO.....	144
SORIN.....	144
PHILIPS	145
TOPSPIN MEDICAL	145
SONOSITE, INC.	145
DATASCOPE CORPORATION.....	145
RESPONSE BIOMEDICAL.....	146
ASTRAZENECA.....	146
BMS & PFIZER.....	146
DECODE GENETICS	146
ENCYSIVE PHARMACEUTICALS INC.....	147
EPIX PHARMACEUTICALS, INC.....	147
LEXICON PHARMACEUTICALS	147
MERCK & COMPANY.....	147
MOMENTA PHARMACEUTICALS, INC.....	147
NILE THERAPEUTICS, INC.....	148
PHARMACOPEIA.....	148
SANOFI-AVENTIS	148
TAKEDA PHARMACEUTICAL.....	149
UNIVERSITY OF NORTH CAROLINA	149
DEVICES.....	149
ABBOTT	149
ABIOMED, INC.....	149
ATS MEDICAL.....	150
CARDIATIS	150

CRYOCATH TECHNOLOGIES, INC.	150
CRYOCOR, INC.	150
EDWARD LIFESCIENCES	151
MEDTRONIC, INC.	151
METHODIST DEBAKEY HEART CENTER.....	151
ST. JUDE MEDICAL, INC.	152
STEM CELLS AND HEART DISEASE.....	152
STEM CELLS AND HEART DISEASE (CONTINUED)	153
PATENT ANALYSIS	154
TOTAL PATENTS	154
PATENTS BY YEAR.....	154
<i>TABLE 78 TOTAL NUMBER OF SIGNIFICANT PATENTS, 2005–2007.....</i>	<i>154</i>
<i>FIGURE 50 NUMBER OF PATENTS, 2005–2007.....</i>	<i>154</i>
<i>FIGURE 51 NUMBER OF PATENTS, SHARE BY YEAR, 2005–2007 (%).....</i>	<i>155</i>
PATENTS BY COUNTRY	155
<i>TABLE 79 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2007.....</i>	<i>156</i>
<i>FIGURE 52 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005–2007</i>	<i>156</i>
DIAGNOSTICS PATENTS.....	157
PATENTS BY YEAR.....	157
<i>TABLE 80 PATENTS FOR DIAGNOSTICS BY YEAR, 2005–2007.....</i>	<i>157</i>
<i>FIGURE 53 PATENTS FOR DIAGNOSTICS BY YEAR, 2005–2007</i>	<i>157</i>
PATENTS BY COUNTRY	158
<i>TABLE 81 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005-2007.....</i>	<i>158</i>
<i>FIGURE 54 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005–2007.....</i>	<i>158</i>
PATENTS BY COMPANY	159
<i>TABLE 82 NUMBER OF PATENTS BY COMPANY FOR DIAGNOSTICS</i>	<i>159</i>
<i>TABLE 82 (CONTINUED).....</i>	<i>160</i>
<i>FIGURE 55 TOTAL NUMBER OF PATENTS BY COMPANY FOR</i>	
<i>DIAGNOSTICS, 2005-2007.....</i>	<i>160</i>
PATENTS BY ASSIGNEE.....	161
<i>TABLE 83 NUMBER OF PATENTS BY ASSIGNEE FOR</i>	
<i>DIAGNOSTICS, 2005–2007</i>	<i>161</i>
<i>FIGURE 56 NUMBER OF PATENTS BY ASSIGNEE FOR</i>	
<i>DIAGNOSTICS, 2005-2007.....</i>	<i>161</i>
DRUG PATENTS.....	162
PATENTS BY COUNTRY	162
<i>TABLE 84 PATENTS BY COUNTRY FOR DRUGS, 2005-2007.....</i>	<i>162</i>
<i>FIGURE 57 PATENTS BY COUNTRY FOR DRUGS, 2005–2007.....</i>	<i>162</i>
PATENTS BY COMPANY	163
<i>TABLE 85 NUMBER OF PATENTS BY COMPANY FOR DRUGS, 2005-</i>	
<i>2007</i>	<i>163</i>
<i>TABLE 85 (CONTINUED).....</i>	<i>164</i>
<i>FIGURE 58 TOTAL NUMBER OF PATENTS BY COMPANY FOR</i>	
<i>DRUGS, 2005–2007</i>	<i>164</i>

Patents by Assignee.....	165
<i>TABLE 86 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES,</i> <i>2005-2007</i>	<i>165</i>
<i>FIGURE 59 NUMBER OF PATENTS BY ASSIGNEE FOR DRUGS,</i> <i>2005-2007.....</i>	<i>165</i>
DEVICE PATENTS	166
PATENTS BY YEAR.....	166
<i>TABLE 87 PATENTS FOR DEVICES BY YEAR, 2005-2007.....</i>	<i>166</i>
<i>FIGURE 60 PATENTS FOR DEVICES BY YEAR, 2005-2007.....</i>	<i>166</i>
PATENTS BY COUNTRY	167
<i>TABLE 88 PATENTS BY COUNTRY FOR DEVICES, 2005-2007.....</i>	<i>167</i>
<i>FIGURE 61 PATENTS BY COUNTRY FOR DEVICES, 2005-2007.....</i>	<i>167</i>
PATENTS BY COMPANY.....	168
<i>TABLE 89 NUMBER OF PATENTS BY COMPANY FOR DEVICES,</i> <i>2005-2007</i>	<i>168</i>
<i>TABLE 89 (CONTINUED).....</i>	<i>169</i>
<i>FIGURE 62 TOTAL NUMBER OF PATENTS BY COMPANY FOR</i> <i>DEVICES, 2005-2007.....</i>	<i>169</i>
PATENTS BY ASSIGNEE.....	170
<i>TABLE 90 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES,</i> <i>2005-2007.....</i>	<i>170</i>
<i>FIGURE 63 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES,</i> <i>2005-2007.....</i>	<i>170</i>
COMPANY PROFILES FOR DIAGNOSTICS	171
ABBOTT LABORATORIES INC.....	171
AXIS-SHIELD PLC.....	171
BAYER AG	172
BECKMAN COULTER INC.....	173
BIOMÉRIEUX INC.....	173
BIOSITE INCORPORATED.....	174
BIOSOUND ESAOTE INC.....	174
CAMBRIDGE HEART INC.....	174
CHOLESTECH	175
COVIDIEN	175
DADE BEHRING INC.....	176
DELTEX MEDICAL GROUP PLC.....	177
EPIX PHARMACEUTICALS, INC.....	177
EP MEDSYSTEMS	177
FONAR CORPORATION	178
GE HEALTHCARE.....	179
HYPERTENSION DIAGNOSTIC INC.....	179
INVERNESS MEDICAL INNOVATIONS, INC.....	180
MALLINCKRODT	180
MEDISON AMERICA INC.....	181

MORTARA INSTRUMENT INC.....	181
OLYMPUS AMERICA INC.	181
ORTHO-CLINICAL DIAGNOSTICS, INC. (JOHNSON & JOHNSON CO.)	182
PHILIPS MEDICAL SYSTEM	182
PREMD INC.....	183
RESPONSE BIOMEDICAL CORP.	183
ROCHE HOLDING	183
SIEMENS	184
SONOSITE	184
SONOSITE (CONTINUED).....	185
COMPANY PROFILES FOR DRUGS	186
ABBOTT LABORATORIES INC.....	186
ASTRAZENECA PLC	186
BAYER HEALTHCARE PHARMACEUTICALS INC.	187
BIOVAIL CORPORATION.....	187
BOEHRINGER INGELHEIM	188
BRISTOL-MYERS SQUIBB COMPANY	188
CV THERAPEUTICS INC.....	188
HOFFMAN-LA ROCHE INC.	189
KRKA GROUP	189
LES LABORATORIES SERVIER	190
MERCK & CO. INC.	190
MERCK KGAA.....	191
NOVARTIS AG	191
PFIZER INC.	192
SANOFI AVENTIS	192
SCHERING PLOUGH	193
SOLVAY S.A.	194
UCB	194
WYETH	194
ZENTIVA N.V.	195
COMPANY PROFILES FOR DEVICES.....	196
AMBU INTERNATIONAL AS	196
ANGIODYNAMICS INC.....	196
ASAHI INTECC CO., LTD.	197
ATS MEDICAL INC.....	197
BACCHUS VASCULAR	198
BIOHEART INC.....	198
BIOSENSOR INTERNATIONAL GROUP	198
BOSTON SCIENTIFIC CORPORATION	199
CARDIMA INC.....	200
CONOR MEDSYSTEMS, LLC	200

COOK GROUP	201
CORDIS CORPORATION (JOHNSON &JOHNSON CO.)	201
COREVALVE	202
C.R. BARD INC.....	202
CRYOCATH	203
CRYOCOR.....	203
DATASCOPE CORP.	204
EDWARD LIFESCIENCES CORP.	204
GOODMAN CO. LTD.....	205
HANSEN MEDICAL	205
HOSPIRA	206
JAPAN LIFELINE.....	206
MEDTRONIC	207
MERIT MEDICAL SYSTEM INC.	207
NMT MEDICAL INC.....	208
POSSIS MEDICAL	208
SORIN GROUP	209
ST.JUDE MEDICAL.....	209
TERUMO.....	210
THORATEC.....	210
VASCULAR SOLUTIONS INC.....	210
WORLD HEART CORP.....	211
ZOLL MEDICAL INC.....	211
APPENDIX	212
<i>TABLE 91 ACRONYMS</i>	212
<i>TABLE 91 (CONTINUED)</i>	213
<i>TABLE 91 (CONTINUED)</i>	214